<DOC>
	<DOCNO>NCT00234676</DOCNO>
	<brief_summary>The primary objective POETRY study ass safety tolerability estrogen replacement therapy ( ERT ) postmenopausal woman Parkinson 's disease ( PD ) ass recruitment study ERT postmenopausal woman PD .</brief_summary>
	<brief_title>POETRY : Study Estrogen Replacement Therapy Postmenopausal Women With Parkinson 's Disease</brief_title>
	<detailed_description>POETRY 8-week study 30 post-menopausal woman Parkinson 's disease ( PD ) enrol six clinical site United States . The study design measure safety tolerability estrogen replacement therapy ( ERT ) . The study also measure ERT affect think behavior , movement activity daily live , well motor fluctuation dyskinesias . Although know gender difference PD , study assess impact symptom management . Women PD usually require less levodopa , likely experience drug-related dyskinesia , commonly report change symptoms menstruation , menopause use hormone , imply hormonal change may impact PD symptom . All perimenopausal woman face decision whether use estrogen replacement therapy ( ERT ) woman PD , information estrogen 's effect PD may facilitate decision-making .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Postmenopausal woman Parkinson 's disease experience levodoparelated motor fluctuation average least 2 hour daily `` '' state confirm home diary Must stable dose carbidopa/levodopa , immediate control release therapy , antidepressant , anxiolytic ( last 30 day ) Insulin dependent diabetes Thyroid disease</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Parkinson disease</keyword>
	<keyword>woman</keyword>
	<keyword>postmenopause</keyword>
	<keyword>estrogen replacement therapy</keyword>
	<keyword>clinical trial</keyword>
</DOC>